Objectives: To perform a cost-effectiveness analysis comparing the use of transarterial radioembolization (TARE) with that of sorafenib in the treatment of patients with intermediate or advanced hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver Cancer staging system. Methods: Patient-level data were consecutively recorded and collected at three oncology centers in Italy. A propensity score matching was performed to compare patients with similar clinical characteristics who underwent TARE or sorafenib treatment. Clinical data from the matched cohorts were used to populate a Markov model to project, on a lifetime horizon, life years, qualityadjusted life years, and economic outcomes associated with TARE and sorafenib for both intermediate and advanced HCC stages. Results: Starting from data covering 389 and 241 patients who underwent TARE and sorafenib treatment, respectively, the propensity score matching yielded a total of 308 matched patients. For intermediatestage patients, the model estimated for TARE versus sorafenib an incremental cost-utility ratio of €3,302/QALY (incremental costeffectiveness ratio of €1,865 per life year gained), whereas for patients in advanced stage TARE dominated (lower costs and greater health improvements) compared with sorafenib. Conclusions: From an Italian health care service perspective, TARE could be a costeffective strategy in comparison with sorafenib for patients with intermediate or advanced HCC. The results from forthcoming randomized controlled trials comparing TARE with sorafenib will be able to confirm or reject the validity of this preliminary evaluation. In the meantime, decision makers can use these results to control and coordinate the diffusion of the technology.
Introduction
Liver cancer is the fifth most common cancer in men and the ninth in women, representing the second most common cause of cancer-related deaths in the world. The highest incidence of liver cancer has been reported for sub-Saharan Africa and Southeast Asia, and the incidence in some of these countries is 10 times higher than reported for United States and Europe [1] . Prognosis of liver cancer is very poor with a mortality-to-incidence ratio of 0.95.
Hepatocellular carcinoma (HCC) represents approximately 75% of primary liver cancers and is a major global health problem. The incidence of HCC increases progressively with age, reaching a peak at 70 years [2] .
Clinical guidelines [3] [4] [5] support surveillance, diagnostic, and treatment practice for the management of patients with HCC. Disease status is defined through the Barcelona Clinic Liver Cancer (BCLC) classification, which takes into account the size and the extent of the primary tumor, liver function, and physiological factors [6] . This staging system categorizes patients with early (stage A), intermediate (stage B), advanced (stage C), or terminal (stage D) HCC. There is a related treatment plan for each stage, ranging from potentially curative therapies (e.g., resection or transplant for early-stage patients) to best supportive care for end-stage patients.
Interventional locoregional treatments are recommended for nonsurgical patients in the intermediate HCC stage. These treatments include intra-arterial transcatheter embolotherapies through a wide range of devices. Systemic therapy is generally recommended for advanced disease stage (BCLC-C), in which therapies are used with the intention to improve survival and/or maintain quality of life without curative intent.
Transarterial radioembolization (TARE), also known as selective internal radiation therapy, is a liver-directed therapy presently used in clinical practice in many countries. TARE is not explicitly recommended, and is considered experimental, in HCC clinical guidelines [3] [4] [5] 7] .
TARE plays a potentially leading role in treating advanced HCC accompanied with portal vein thrombosis (PVT) involvement, a clinically relevant scenario occurring in about 40% of patients [8] . TARE is a microembolic procedure causing minimal occlusion of hepatic arteries; therefore, it can be safely used in patients with PVT without compromising blood flow to the hepatic parenchyma [9] . Macrovascular tumor invasion is a shared contraindication to transplantation, ablation, and any kind of chemoembolization technique [3, 4] . Treatments for patients with HCC accompanied with PVT are more limited than for those without PVT. Transarterial chemoembolization (TACE) is considered contraindicated in cases of PVT because of its high embolic effect [8] , and the alternative to TARE for patients with PVT is only systemic therapy with sorafenib.
According to the latest release of the European Society for Medical Oncology guidelines, TARE may therefore be competitive with sorafenib in patients in the intermediate stage who failed chemoembolization treatment or in advanced patients with PVT with no extrahepatic spread and good liver function [5] . At present in Italy this treatment is offered to about 4% of patients with intermediate or advanced HCC [10, 11] .
The evidence that supports the use of TARE in HCC treatment is mainly based on retrospective or prospective observational studies [12] [13] [14] [15] [16] , and no cost-effectiveness analyses have been performed comparing the use of TARE with that of sorafenib for the treatment of patients with HCC. Two randomized controlled trials (RCTs) comparing TARE with sorafenib are ongoing at present (YES-P: NCT01887717; SARAH: NCT01482442). Although RCTs are the most universally accepted and robust experimental designs to estimate treatment effects, they are often conducted in highly selected populations and may lack external validity [17, 18] . Moreover, randomization is not always feasible because of technical or ethical issues, such as insufficient evidence equipoise. In the meantime, however, real-world data are accruing because of the diffusion of this innovative therapy in the clinical practice.
The aim of the present study was to perform a costeffectiveness analysis comparing TARE with sorafenib in patients with intermediate or advanced HCC using real-world clinical data collected at three major Italian oncology centers. TARE is an established and simultaneously experimental procedure used in Italy for the treatment of intermediate and advanced HCC. The unmet clinical needs for this patient group are substantial, and this study can inform decision makers in Italy regionally and nationally in due course.
Methods

Target Population and Interventions
The study focused on patients with intermediate or advanced HCC treated with TARE (which alongside the TARE procedure includes a bundle of inpatient procedures including diagnostic tests) or sorafenib (target dose, 800 mg/d).
Overall survival (OS) and progression-free survival (PFS), defined as the time from the start of the treatment to progression or death, whichever occurred first, were identified as the most important health outcomes.
Patient-level data were prospectively collected from 2005 to 2015 at three oncology centers with the highest volume of TARE procedure use in Italy (National Cancer Institute, Milan; Azienda Ospedaliero-Universitaria Pisana, Pisa; and Azienda OspedalieroUniversitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna).
Because data from the three centers referred to different index years (Milan, 2007; Bologna, 2005 ; and Pisa, 2013), we compared the OS and PFS of patients treated in the first 2 years versus patients treated in the following years to check that no learning curve effect was present.
After the exclusion of patients with metastatic disease, early or terminal disease stage, and patients with metastases, a quality check was performed to assess incomplete clinical data (OS or PFS), out-of-range values, and consistency of data (OS and PFS greater than 0, OS greater than or equal to PFS) [19] . Available data have been gathered and merged to build a new data set to populate the cost-effectiveness model. To compare patients with comparable prognostic factors in the TARE and sorafenib groups, a one-to-one nearest neighbor propensity score matching (PSM) procedure [20] was performed. Because a systematic literature review [21] reported PVT, alpha-fetoprotein, Child-Pugh class, and tumor size as the most robust predictors for survival for patients with HCC, these patients' characteristics and prognostic factors were taken into account by the clinical advisors and the modeling team. In particular, Child-Pugh score uses five clinical measures of liver disease (total bilirubin, serum albumin, prothrombin time, ascites, and hepatic encephalopathy) to classify patients according to different expected survivals (at 2 years: A, 85%; B, 57%; and C, 35%) [22] .
Child-Pugh score, PVT status, and a proxy for tumor size (i.e., number of nodules) were judged as the main prognostic factors to be considered in the PSM. A second round of data filtering was performed excluding patients with incomplete data on the PSM variables, and then a logit function of the probability of receiving either treatment for a patient with these baseline characteristics was built. According to Tandon and Garcia-Tsao [21] , patients' demographic characteristics were not included in the analysis.
Different simulations were made, varying the radius from 0.001 to 1, to find an adequate balance between bias reduction and common support size. Patients were further classified into being in intermediate and advanced stages according to the BCLC staging system to perform subgroup analyses. STATA 11 software (StataCorp, College Station, TX) and the command psmatch2 [23] were used to perform the PSM.
The Model
A Markov multistate model was selected for this economic evaluation and developed to project lifetime health (life years and quality-adjusted life years [QALYs] ) and economic outcomes associated with TARE and sorafenib strategies for both intermediate and advanced HCC stages. Markov models are commonly used in economic evaluations for oncology treatments by health technology assessment bodies internationally. The model structure and problem formulation have been validated during two consecutive focus group meetings by the clinical expert group. In particular, in the first one, an evaluation of face validity of the model's structure and problem formulation was conducted, whereas during the second meeting a discussion on the evidence used to populate the model and on the results obtained was undertaken [24] .
The health states in the implemented Markov model include ( Fig. 1) 
health states for patients with intermediate or advanced HCC undergoing TARE or sorafenib treatment have been estimated from the matched population. Different curve functions (i.e., Weibull, Gompertz, and exponential) have been fitted for the PFS curves emerging from the two matched cohorts according to treatment strategy. The performance of the different fittings was assessed according to standard evaluation criteria (Bayesian information criterion), and the relevant transition probability was derived accordingly.
Transition probabilities from disease progression to death were considered time-dependent and were calibrated to approximate the Kaplan-Meier postprogression survival curves as measured by the area under the curve calculated on the matched patient-level data.
Mortality rates were further adjusted for age and sex according to Italian mortality tables (National Institute of Statistics) to take into account deaths caused by other comorbidities ("death for other causes" state).
For patients undergoing sorafenib treatment, a clinical assessment is performed each month, and hence a 1-month Markov cycle length was chosen for baseline analysis. To consider mean, rather than median effects, a lifetime horizon was chosen [25] .
The model was constructed using TreeAge software (TreeAge Software, Inc., Williamstown, MA).
Health Care Resource Consumption and Costs
The model includes only direct health resource consumption (direct costs) ( Table 1 ) based on 2015 base-case values (expressed in euros). Data on costs were obtained from diagnosis related group (DRG) reimbursement rates and official tariffs from Lombardy to reflect an Italian regional health care system perspective.
After discussions with the clinical expert group, the treatment protocol for TARE was confirmed. The treatment pathway proceeds from a first oncology visit to a procedure simulation (DRG 203), laboratory examinations, and the treatment itself (DRG 409). After 1 month, a follow-up oncology visit and laboratory examinations are repeated, including an abdomen computerized tomography (CT) scan. Such follow-ups are conducted every 3 months [26] .
For sorafenib treatment, after the first oncology visit and laboratory examinations, sorafenib (112 cp 200 mg each, hospital cost €3,536.17) is given monthly to each patient until disease progression. A payment-by-result scheme is in place for sorafenib in Italy, whereby for each nonresponder in the first 2 months, the drug manufacturer is expected to cover reimbursement costs up to a maximum of two packages). Therefore, an abdomen CT scan is performed 2 months after sorafenib initiation to verify the disease state classification. Otherwise, follow-up is the same as in TARE.
Subsequent treatments were identified from the available cohort data and incorporated in the model. Best supportive care included use of off-label drugs, systemic chemotherapy of varying dose, and duration, which were not considered in the model. Liver decompensation was recognized by the clinical experts as the most economically and clinically relevant adverse event leading to hospitalization (DRG 464; see Table 1 ). Liver transplantation costs were based on the DRG 408 tariff, whereas lifetime costs after the intervention were derived from the literature [27] and were estimated at €6,182 per year. Prices were inflated to 2015 values using the Harmonised Index of Consumer Prices (Datastream TM , Thomson Reuters, New York, NY) for Italy.
Quality-of-Life Estimates
Health-related quality-of-life measures were not available in the patient-level data set and hence a literature search was conducted. The utility coefficients for patients with HCC were obtained from the Cost-Effectiveness Analysis Registry, a comprehensive database of more than 4000 cost-utility analyses on a wide variety of diseases and treatments [28] . For each health state considered in the model (stable disease, progression, and liver transplantation) excluding death, utility coefficients were retrieved and an average value was derived. A summary of the retrieved utilities and related mean values is presented in Appendix 
Baseline Analyses
Both incremental cost-effectiveness ratio (ICER) and incremental cost-utility ratio (ICUR) of TARE versus sorafenib were calculated by dividing the incremental cost by the incremental health improvement. Life years, QALYs, and costs were discounted at a 3.5% yearly rate [46] . Transition probabilities, costs, and utilities were entered into the model along with a distribution: beta for utilities and proportions of patients performing after treatments and gamma for costs and number of TARE treatments (see Appendix Table 2 in Supplemental Materials found at http://dx. doi.org/10.1016/j.jval.2016.09.2397). Deterministic and probabilistic sensitivity analyses were performed to test the robustness of the model. Univariate analyses were performed according to time horizon, mean number of TARE procedures per patient, discount rate, probability of liver transplantation, mean age of the cohort, and price of a 112-cp pack of sorafenib excluding the pay-byresult price.
Second-order Monte-Carlo simulations (10,000 iterations) were conducted for intermediate and advanced stages to take into account parameter variability as described in Appendix Table 2 in Supplemental Materials and the resulting scatterplots were plotted onto a cost-effectiveness plane.
Scenario Analyses
To investigate model structural uncertainty, different analyses were performed. A scenario analysis was performed including the cost of best supportive care and terminal care reported in the literature for the Italian setting (€4,142 [2012] corresponding to €4,192 [2015] ) [47] .
Another scenario analysis was performed including in the model all registered events of grade III/IV experienced during the treatment with TARE or sorafenib available from the subset of patients (N ¼ 66) collected at Bologna Oncology Centre (Azienda Fig. 1 -Markov model. The health states included are stable disease, disease progression, and death. In the intermediate stage, an additional state was included to take into account the possibility of liver transplantation. A hypothetical cohort of 68-year-old (i.e., mean age of the matched population) patients with HCC enter the Markov process in the stable state (i.e., with stable HCC). HCC, hepatocellular carcinoma.
Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna).
Other analyses were performed excluding death from causes other than the disease, and considering a different model structure that distinguishes patients according to the best radiological response (stable disease, complete or partial response according to mRECIST criteria [48] ). Because no specific utility weights were found in the literature to distinguish among the cited states, we considered the distribution of values obtained from the different studies (as reported in Appendix Table 1 
Results
Target Population
Data covering 389 patients who underwent TARE and 241 patients who underwent sorafenib treatment were retrieved. Out of these patients, 43 (6%) and 24 (4%) patients, respectively, were excluded who presented with either metastatic disease or a disease stage outside the scope of this analysis (e.g., BCLC-A or BCLC-D). Sixty-four patients (10%) with incomplete survival data were excluded, and two patients were excluded because of missing data on the main parameters (presence of PVT and number of nodules).
PSM was performed on 497 patients by varying the caliper radius. For values less than or equal to 0.2, the PSM yielded a sample of 308 patients with identical clinical characteristics (100% reduction bias on all the variables), whereas for values higher than 0.2 the sample comprised a higher number of patients but with a bias reduction less than 100% for all the considered variables (see Appendix in Supplemental Materials for further details).
The final database resulted in 308 patients (154 TARE and 154 sorafenib) with matched clinical characteristics. Because the small difference in mean age between the matched cohorts seemed not to influence the clinical outcomes, a mean age of 68 years was considered for both cohorts of patients.
A greater number of patients in the TARE cohort (71%) belonged to the intermediate stage compared with those in the sorafenib cohort (49%). A summary of the patients' characteristics before and after the matching is presented in Table 2 .
In the final cohorts, the mean survivals obtained for patients in the intermediate stage (BCLC-B) undergoing TARE and sorafenib treatment were 24 (median 18.5) and 18.4 (median 13) months, respectively. These values decreased respectively to 14.9 (median 11.2) and 16.1 (median 11.3) months for patients in the advanced stage (BCLC-C).
Curve Fitting
PFS curves for TARE strategy were better approximated using Weibull and Gompertz functions for intermediate and advanced stages, respectively. PFS curves for sorafenib strategy (intermediate and advanced stages) were better approximated by exponential functions (see Appendix Figure 1 in Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.2016.09.2397). For each survival curve, we verified, with a simulation of the same duration of the cohort follow-up, that the difference between the average survival calculated from patient-level data and the average survival estimated by the model was less than 10 days for each event of interest (death or progression) for each disease CT, computed tomography; DRG, diagnosis related group; gpt, glutamic pyruvic transaminase; PEI, percutaneous ethanol injection; RFA, radiofrequency ablation; TACE, transarterial chemoembolization; TARE, transarterial radioembolization. * Every 3 mo.
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stage. Model transition probabilities are presented in Appendix Table 3 
Baseline Results
The mean number of TARE treatments per patient was 1. Average life expectancy in the advanced stage was estimated to be 1.445 (0.639 QALYs) and 1.306 (0.568 QALYs) years, respectively, for patients undergoing TARE and sorafenib regimen. The estimated mean costs per patient were €21,961 and €30,750 for patients undergoing TARE and sorafenib treatment, respectively. In patients in advanced stage, TARE dominated (lower costs and greater health improvements) compared with sorafenib.
The model results for the two scenarios are presented in Table 3 . Table 4 presents the results of one-way sensitivity analyses performed on the main model parameters. Variation in the mean number of TARE procedures used per patient (from one to three) can greatly influence the ICER, most significantly for patients in the advanced stage.
Analyses
Variations in patient age, monthly probability of liver transplantation, and discount rate did not influence the ICUR for advanced disease stage. In intermediate-stage patients, a monthly probability of liver transplantation lower than 0.0021, in the first 6 years, showed that TARE could be a dominant strategy. In the same group of patients, an age variation from 60 to 80 years showed a decreasing ICUR. A similar trend was observed when discount rates were increased from 0% to 10%.
With regard to sorafenib costs, for advanced disease stage patients a price reduction of 50% could lead to an ICUR of around €37,000/QALY; for intermediate-stage patients, such a reduction could lead to a more limited increase in the ICUR (€20,529/QALY). Testing sorafenib price without the pay-by-result scheme showed a reduction in only the ICUR for intermediate-stage patients, whereas for advanced stage of disease TARE still remained dominant.
The scenario analysis performed including the cost of best supportive care for terminally ill patients yielded for TARE lifetime costs of €34,627 and €25,804 for intermediate and advanced stages, respectively. For sorafenib treatment, the values reported were €33,132 and €34,661, respectively. On the basis of these data, in intermediate-stage patients, the ICUR of TARE versus that of sorafenib decreased to €2,771 in comparison with the baseline analysis, whereas TARE was confirmed a dominant strategy for advanced disease stage patients.
With regard to the analysis on severe adverse events (grade III/IV), patients undergoing TARE experienced cholecystitis (6.7% intermediate stage, about 50% advanced stage), whereas intermediate-stage patients undergoing sorafenib treatment mainly experienced metabolic disorders (10.3%), fatigue, asthenia, erythema, and hand-foot syndrome (3.4% each). Advanced disease stage patients undergoing sorafenib treatment experienced pain (5%), fatigue (15%), and nausea (10%). After the 
inclusion of these frequencies and related DRG reimbursements (for detailed data, see Appendix Table 5 
Discussion
TARE has emerged as a locoregional treatment option for patients with unresectable HCC. It is a sophisticated therapy, available only in specialized centers, and requiring intervention from a multidisciplinary team (including interventional radiology, nuclear medicine, surgery, hepatology, and medical oncology) [49] . TARE treatment may be competitive with sorafenib, an oral antineoplastic agent, used in intermediate-stage patients who failed chemoembolization or advanced disease stage patients with or without PVT, with no extrahepatic spread and good liver function. Although TARE showed promising clinical efficacy with a good safety profile in phase II studies and registries [12] , the use of this treatment is not formally recommended in clinical guidelines at present.
Large RCTs comparing TARE with sorafenib are ongoing but no clinical results have been published to date. TARE uptake in clinical practice is growing in Italy and in other countries [50] . Because the diffusion of medical devices generally precedes experimental evidence, decision makers such as physicians and health care organizations are already familiar with the technology before comparative clinical evidence is available. The use of real-world data to support decision making is therefore of great interest [51] . This issue is common across medical devices and has been observed for other technologies [52] .
The present study aimed to evaluate the cost-effectiveness of TARE versus sorafenib to assess the value of presently available treatment options in clinical practice.
The analysis was performed using observational real-world data from three major oncology centers in Italy. Life expectancies derived from this cohort are comparable with those reported in the literature for TARE, for intermediate stage, ranging from 3.6 to 18.4 months, and for advanced stage, ranging from 6.4 to 13.8 months [53] . Similarly for sorafenib treatment, life expectancies are comparable with the outcomes of a subgroup analysis of the Sorafenib Hepatocellular carcinoma Assessment Randomized Protocol (SHARP) trial [54] , which reported median survivals of 9.7 and 14.5 months for intermediate and advanced stages, respectively. 
The results from this analysis suggest that from an Italian health care service perspective TARE could be a cost-effective strategy compared with sorafenib treatment for patients in intermediate or advanced HCC stage. Sensitivity and scenario analyses showed the robustness of the baseline results: only variations in the time horizon and in the number of TARE treatments per patient could lead to an ICUR of more than €50,000/QALY gained. The number of TARE treatments per patient, however, is unlikely to be greater than 1.5. Furthermore, probabilistic sensitivity analyses confirmed the results, with most of the simulations (almost all for intermediate stage) lying below the commonly accepted ICUR threshold representing value for money.
In the literature, a paucity of studies present a costeffectiveness analysis comparing TARE with sorafenib for the treatment of patients with HCC. To our knowledge, only Chaplin et al. [55] published an abstract reporting results for the UK setting. The study, based on published evidences, showed that TARE can be considered a dominant strategy in comparison with sorafenib (TARE £21,441 vs. sorafenib £34,050; QALY gain of 0.27 for TARE). Other studies estimated the costs related to TARE or sorafenib for patients with HCC, with few of them in the Italian setting. From the Italian health care service perspective, one study [47] reported total costs of €24,224 and €14,841 for sorafenib treatment for intermediate and advanced stages, respectively. Anyway, the time horizon was limited to 5 years and the underlying model did not include the management of side effects and following treatments. Another study [45] reported a cost of €22,500 from the Italian health care service perspective for a treatment with sorafenib as a bridge to liver transplantation. In this case, the cost accounted for 5 months of treatment considering 600 mg per day. A more recent study [11] investigated the costs for TARE and sorafenib treatment in patients with HCC from the hospital perspective, reporting costs of €26,106 and €12,215, respectively. The analysis, based on a survey, considered the costs for professionals, drugs, consumables, and overheads only for first-line treatments (6.08 months for sorafenib and 1.5 TARE sessions per patient).
The present study has a number of limitations. First, the clinical effectiveness was derived on the matched databases with a limited number of patients in selected major oncology centers, and therefore the generalizability of the real-world patient data collected to the broader Italian HCC population could not be tested. Moreover, in propensity score estimation, considering only a few covariates may alter the estimation and interpretation of other hidden nonobservable covariates, and hence the generalizability of the results has to be treated cautiously [56] . Second, the model lifetime results are greatly influenced by the survival curve extrapolations derived from non-RCT data.
Continuous monitoring and recording of survival data in this population will be useful to confirm the assumptions made, not least once major RCTs report survival data.
Third, health care resource consumption was retrieved from the clinical data only for cancer-related therapies (i.e., number of TARE treatments and sorafenib treatment duration), whereas for the follow-up period the schedule for visits and examinations was applied. This approach could have led to differences between the estimated and actual health care resource consumption.
Fourth, with regard to adverse events, because of the lack of reported data, liver decompensation was considered as the main consequence due to TARE or sorafenib; anyway, the scenario analysis conducted considering other severe side effects experienced by a subset of patients confirmed that TARE can be considered a cost-effective treatment in comparison with sorafenib for patients with HCC. Frequencies of severe side effects experienced by advanced disease stage patients treated with sorafenib (30%) resulted in line with the ones presented by the GIDEON study [57] , which reported grade III/IV adverse events in 29% of cases (BCLC-C group). For intermediate-stage patients, severe adverse events frequency used in the model (24%) can be considered a conservative estimate of the total effect as reported by the cited study (34%).
Fifth, best supportive care and terminal care were not considered in the base-case model but may have a significant impact on total costs of treatment care; anyway, the scenario analysis performed considering cost data from an Italian study [47] confirmed the conclusions of the baseline model.
Finally, survivals and resource consumption related to patients treated with new technologies, such as TARE, may be influenced by the underlying learning curve related to the experience of the operators. Nevertheless, a preliminary analysis performed comparing survival data before and after the first 2 years from the introduction of the new technology did not show any significant effect.
Conclusions
TARE seems to be a valid treatment option for patients in intermediate and advanced HCC stages. The trial results from forthcoming RCTs comparing TARE with sorafenib will increase the clinical evidence qualitatively to confirm or reject the validity of this preliminary evaluation. In the meantime, decision makers can make use of these results to issue preliminary coverage recommendations, for approval in defined target patient populations, or using conditional approval methods. ( 2 0 1 7 ) 3 3 6 -3 4 4 
